OP024 Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s disease: the OPERA II study

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Crohns & Colitis

• Publication date

  2018-01-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ECCO-JCC/JJX180.023
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Novel and Emerging Therapies for Inflammatory Bowel Disease

  2021cites this paper
• New targets in inflammatory bowel disease therapy: 2021

  2021cites this paper
• Current Status of Medical Therapy for Inflammatory Bowel Disease: The Wealth of Medications

  2020cites this paper
• The IBD Therapeutic Pipeline is Primed to Produce

  2019cites this paper
• Rational and clinical development of the anti-MAdCAM monoclonal antibody for the treatment of IBD

  2019cites this paper
• Targeting Remission in Moderate-to-Severe Crohn's Disease.

  2018cites this paper
• Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts.

  2018cites this paper